Printer Friendly

Anti-CMV IgM titer predicts CMV disease after liver transplantation.

High levels of IgM antibody to cytomegalovirus (CMV) are an independent risk factor for the development of CMV infection after liver transplantation, according to researchers at the Royal Free and University College Medical School in London, UK.

Among 19 liver transplant recipients who developed CMV disease, 18 had high CMV-specific IgM antibody levels as measured by automated AxSYM assay. IgM was detected before CMV DNA (by PCR) in 2 patients, with both tests concurrently positive in 7 patients. DNA was detected before IgM in 8 patients. In addition, AxSYM results were positive in 11 of 21 patients without evidence of CMV disease, with all of these patients also positive for CMV DNA. Maximum IgM titer was a predictor of CMV disease independent of methylprednisolone use and donor and recipient serostatus, though viral load remained a significant independent risk factor for disease.

The researchers concluded that analyzing liver transplant recipients by both PCR and AxSYM assay may produce complimentary results. (Journal of Infectious Disease 2000;182:1610-1615.)
COPYRIGHT 2000 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Royal Free and University College Medical School study cytomegalovirus
Comment:Anti-CMV IgM titer predicts CMV disease after liver transplantation.(Royal Free and University College Medical School study cytomegalovirus)
Publication:Transplant News
Article Type:Brief Article
Geographic Code:4EUUK
Date:Dec 15, 2000
Words:166
Previous Article:Selected gene therapy for head and neck cancer may be feasible.
Next Article:Cyclosporine plus delay of at least 80 days improve second stem cell transplants.
Topics:


Related Articles
Survival bonus for people with AIDS.
MedImmune receives approval from FDA for CytoGam to treat expanded number of organs transplanted.
Treatment with valacyclovir after kidney transplant reduces risk of CMV.
Anti-CMV killer T-cells suppressed after liver transplantation.
Guillain-Barre syndrome, greater Paris area.
Active cytomegalovirus infection in patients with septic shock.
ViroPharma initiates Phase 3 study of maribavir in liver transplant patients.
Primary versus nonprimary cytomegalovirus infection during pregnancy, Israel.
[beta]-herpesviruses in febrile children with cancer.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters